Company intelligence / Profile preview
Loma Therapeutics
Copenhagen, Denmarklomatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Loma Therapeutics has demonstrated promising pre-clinical results with its broad-spectrum, viral vector-based immunotherapy targeting multiple stages of the HPV life cycle. The therapy aims to activate cytotoxic T cells against both infected and cancerous cells with potentially fewer side effects than current standards like surgery or chemotherapy. Head-to-head studies are ongoing to demonstrate superiority over competitors; no clinical trial data yet available.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Viral vector-based immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Loma Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Loma Therapeutics.